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ABSTRACT 
Background: Inappropriate use of antimicrobials in the healthcare setting is associated 
with consequences including antimicrobial resistance, Clostridium difficile infection 
(CDI),  adverse drug reactions, and increased healthcare costs.  To combat this, hospitals 
are creating antimicrobial stewardship programs (ASPs) which seek to optimize 
antimicrobial utilization.  To date, no studies have been done to assess adherence to an 
ASP in a rehabilitation hospital setting.  The objective of this study is to evaluate 
prescriber compliance to treatment pathways for common infections before and after ASP 
implementation.  
Methods: This was a retrospective cohort study of patients admitted to the Rehabilitation 
Hospital of Indiana (RHI) who received an antibiotic between October 1, 2015-December 
31, 2015 (pre-ASP group) and January 1, 2016-September 30, 2016 (post-ASP group) for 
one of the following indications: pneumonia, urinary tract infection, CDI, bone and joint 
infection, skin or skin structure infection, febrile neutropenia, or central/peripherally 
inserted central catheter line bloodstream infection.  Data extracted from the hospital’s 
electronic medical record system included patient demographic and clinical information, 
laboratory data, culture and susceptibility results, and antibiotic information.  The 
primary outcome of this study was prescriber compliance to treatment pathways defined 
as correct drug based on the documented indication before and after the implementation 
of the antimicrobial stewardship program on January 1, 2016.  Descriptive statistics were 
performed to analyze baseline characteristics and culture data, as well as antimicrobial 
class, indication, and overall compliance to the guideline-based treatment pathways.   
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Results: Data was extracted from the hospital’s electronic medical record system for 381 
patients (n=381) who received an antibiotic at RHI.  There were 121 and 260 patients 
included in the pre- and post-ASP study groups, respectively.  Urinary tract infections 
were the most common infection for which antibiotics were prescribed (n=293; 76.9%).  
The three most common antibiotics prescribed were ciprofloxacin (n=101; 26.5%), 
sulfamethoxazole/trimethoprim (n=81; 21.3%), and nitrofurantoin (n=49; 12.9%).  
Compliance was found to be 81% in the pre-ASP group and 78.5% in the post-ASP group 
(p=0.571).  Overall compliance was found to be the highest (100% in both pre- and post-
ASP groups) for osteomyelitis infections and CDI.  Urinary tract infections had the next 
highest rate of compliance in both the pre- and post-ASP groups (86.5% and 81.7% 
respectively). 
Conclusions: No difference in rates of prescriber compliance to guideline-based 
treatment pathways was found in the pre- and post-ASP groups.  Urinary tract infections 
were found to be the most common indication requiring antimicrobial usage at RHI and 
had the third highest rate of compliance out of the infections included in this study.  Our 
study highlights a need for further investigation regarding the impact of the ASP on 
appropriate antimicrobial dose, duration of therapy, administration, and de-escalation 
based on culture data.  Additionally, our study identified a need for formal prescriber 
education focusing on how to utilize the treatment pathways, especially for those 
infections with the lowest compliance rates. 
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BACKGROUND 
The inappropriate use of antimicrobials is a definite and serious problem in the 
healthcare setting.  According to the Centers for Disease Control and Prevention (CDC), 
20-50% of all antibiotics prescribed in United States (US) acute care hospitals are either 
unnecessary or inappropriate.1  The most common inadvertent consequences of misusing 
antimicrobials include antimicrobial resistance, Clostridium difficile infection (CDI), 
adverse drug reactions, and increased health care costs.2 
The prevalence of infections caused by multidrug-resistant organisms (MDROs) 
continues to increase.  Currently, around two million people are infected with antibiotic-
resistant organisms each year with 23,000 deaths.3  Unlike other medications, both the 
use and misuse of antibiotics accelerates the spread of resistant organisms that can impact 
the health of patients who aren’t even directly exposed to them.1  Multi-drug resistant 
organism infections, including methicillin-resistant Staphylococcus aureus (MRSA), 
vancomycin-resistant enterococcus (VRE), and extended-spectrum beta-lactamase 
(ESBL)-producing gram-negative rods, are associated with increased mortality, 
prolonged hospital stays, and higher hospitalization costs.4  New MDROs have emerged 
for which there are limited to no effective treatment options such as carbapenem-resistant 
Enterobacteriaceae (CRE).  Infections with CRE are very difficult to treat and are deadly 
in up to 50% of patients who become infected.5 
To further compound the issue of resistance, today’s antibiotic pipeline is nearly 
dry with only a “handful” of large pharmaceutical companies and smaller biotech firms 
engaged in antibiotic development.6  Between 1999 and 2014, the FDA only approved 
two systemic antibiotics representing an 88% drop from the mid-1980s.7  This can largely 
be attributed to the fact that pharmaceutical companies can make greater profits on drugs  
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used for chronic conditions such as HMG-CoA reductase inhibitors and antidepressants.7  
Consequently, the rate of emergence of antimicrobial resistance far exceeds new 
antimicrobial discovery and development.8,9 
Clostridium difficile infection is the leading cause of healthcare-associated 
diarrhea in adults and its incidence has markedly increased over the past decade.8  In 
2011, CDI was estimated to cause almost half a million infections in the US and 29,000 
deaths.5  Prior antibiotic use is one of the most important risk factors for developing CDI, 
and antibiotic misuse or overuse strongly contributes to the infection proliferation and 
transmission.8,10  Broad-spectrum antibiotics, especially cephalosporins and 
fluoroquinolones, as well as clindamycin are considered high-risk for CDI 
development.11  Prevention of CDI is best achieved by utilizing infection control 
recommendations and careful antibiotic use.5  
A third consequence of inappropriate antimicrobial utilization is the increased risk 
of adverse drug reactions and toxicities.  Antibiotic-associated diarrhea occurs in 10-25% 
of patients treated with amoxicillin-clavulanate and 2-5% of patients treated with 
cephalosporins, fluoroquinolones, macrolides, and tetracyclines.12  Nephrotoxicity has 
been reported with intravenous aminoglycosides, amphotericin, and vancomycin.12  Up to 
one-quarter of women treated with a short course of oral antibiotics develop symptomatic 
vulvovaginal candidiasis.12  Fluoroquinolones are associated with tendon rupture, retinal 
detachment, and delirium.12  Life-threatening dermatologic complications such as Steven-
Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been implicated 
with sulfonamides and beta-lactams.12  Patient groups most at risk for adverse reactions 
include the elderly, patients with renal dysfunction or significant cardiac disease, and 
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those on multiple medications.12  Since antibiotics can cause numerous unpleasant 
adverse effects including life-threatening allergic reactions, it is important to decide if the 
efficacy outweighs the potential for toxicity.2 
Along with increasing the risk to patient safety, the inappropriate use of 
antibiotics can increase otherwise avoidable healthcare costs.  Unnecessary and 
duplicative antibiotics in 500 US hospitals over a 4-year period was associated with an 
estimated $12 million in excess costs and 148,589 days of redundant therapy.13  Seventy-
eight percent of hospitals had evidence of potentially unnecessary combinations of 
antibiotics being administered for two or more days over the time period, resulting in an 
estimated $163 million that could be saved when considering all US hospitals.13  
To help combat inappropriate antibiotic use, hospitals are creating antimicrobial 
stewardship programs.  An antimicrobial stewardship program (ASP) is an institutional 
antimicrobial management program, usually led by an infectious disease physician and 
clinical pharmacist, which seeks to optimize antimicrobial use.14  Antimicrobial 
stewardship programs help prescribers apply evidence-based knowledge to treat 
infections and optimize doses while minimizing adverse drug reactions.14  The primary 
goal of antibiotic stewardship is to optimize clinical outcomes while reducing toxicity, 
the selection of pathogenic organisms like C. difficile, and the emergence of resistance.15  
A secondary goal is to decrease health care costs without adversely impacting quality of 
care.15  
The Rehabilitation Hospital of Indiana (RHI) is an acute care specialty-based 
rehabilitation hospital located in Indianapolis and owned by both Indiana University 
Health and St. Vincent Health.  The hospital mainly specializes in the rehabilitation of 
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stroke, spinal cord injury, and traumatic brain injury patients by providing inpatient 
medical care as well as daily physical and occupational therapy.  At the beginning of 
2015, RHI formed an Antibiotic Stewardship Committee.  The committee is composed of 
a champion physician, clinical pharmacist, infectious disease physician, program 
facilitator, quality director, infection control nurse, and nursing program director.  Goals 
of the committee include the following: safe and appropriate antibiotic dosing, 
responsible use of broad spectrum agents, optimized duration of therapy, reduced 
antimicrobial expenses, and preventable antimicrobial resistance.  
During the latter part of 2015, antimicrobial treatment pathways were developed for 
the following most common infections encountered at RHI: pneumonia, bone and joint 
infections, urinary tract infections (UTI), febrile neutropenia, CDI, skin and skin structure 
infections, and catheter-related bloodstream infections.  The RHI guideline-based 
treatment pathways were created using the most up-to-date Infectious Diseases Society of 
America (IDSA) guidelines as of 2015 and only included antimicrobials on the RHI 
formulary.  The RHI guidelines indicate appropriate empiric therapy, directed therapy, 
alternative agents, and those antibiotics that have prescribing restrictions (Appendix A).  
During the implementation phase, antimicrobial order forms were created to change the 
prescribing process.  Although there are currently no electronic hard stops when 
prescribers order restricted antibiotics, the clinical pharmacist must contact the provider 
and confirm proper indication for the agent before verifying and processing the order.  
There are some antibiotics requiring an internal medicine or infectious disease consult 
before they can be ordered (Appendix B).  If the prescribing physicians follow the 
treatment pathway flowsheets before prescribing an antibiotic, there ideally would be 
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little to no clinical pharmacist intervention necessary at the time of ordering.  The 
objective of the proposed study is to evaluate prescriber compliance to the outlined 
treatment pathways based on the appropriateness of the antimicrobial regimen prescribed 
for the indication.  
THESIS STATEMENT 
Following introduction of an ASP in a rehabilitation hospital, it is predicted that a higher 
percentage of prescribers are adhering to guideline-based treatment pathways when 
prescribing antimicrobial agents in comparison with the period prior to ASP 
implementation.  
STUDY OBJECTIVE 
The objective of the proposed study is to evaluate prescriber compliance to the outlined 
treatment pathways based on the appropriateness of the antimicrobial regimen prescribed 
for the indication.  
NEED FOR STUDY 
Effective January 1, 2017, the Centers for Medicare & Medicaid Services (CMS) issued a 
new requirement stating that hospitals must have an ASP to participate in Medicare and 
Medicaid reimbursement.16  Additionally, the National Action Plan for Combating 
Antibiotic-Resistant Bacteria, issued by the White House in March 2015, calls for the 
establishment of ASPs in all acute care hospitals by 2020.11  Antimicrobial stewardship 
programs can be implemented in a variety of ways in any hospital.3  There are no studies 
that exist which evaluate the effectiveness of ASPs in a specialty rehabilitation hospital 
setting.  In the time since the antimicrobial stewardship program was initiated at RHI on 
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January 1, 2016, there has not been any significant research conducted to examine the 
extent of the program’s success.  Due to its recent implementation, it is not yet practical 
to look at the effects of the program on reducing resistance or healthcare costs.  It is first 
necessary to examine whether prescribing physicians are complying with the guideline-
based treatment pathways outlined in the program before further metrics can be 
conducted.  
METHODS 
This was a retrospective cohort study conducted at RHI and IRB-approved by Butler 
University.  Eligible patients were identified using a pharmacy computer system-
generated report of patients with antibiotic orders for selected indications during the 
specified time frame.  Patients were included if they were greater than 18 years of age 
and received an antibiotic at RHI between October 1, 2015 and September 30, 2016 for 
one of the following indications: pneumonia, UTI, CDI, bone and joint infection, skin or 
skin structure infection, febrile neutropenia, or central/peripherally inserted central 
catheter line bloodstream infection.  Patients were excluded if they received an antibiotic 
for less than 24 hours.  The pre-ASP group included patients receiving an antibiotic 
between October 1, 2015 and December 31, 2015 (Quarter 4 2015).  The post-ASP group 
was comprised of patients receiving an antibiotic between January 1, 2016 and 
September 30, 2016 (Quarters 1-3 2016).  Data was extracted from the hospital’s 
electronic medical record system, and included patient demographics (age, gender, actual 
body weight, antibiotic allergies), laboratory data (white blood cell count, serum 
creatinine), temperature, antibiotic indication, culture and susceptibility results (culture 
location, isolate, susceptibility to antibiotic), and antibiotic information (drug, class, dose, 
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route, frequency, doses administered, total days of therapy).  It was also documented 
whether prescribers followed the guideline-based pathways when prescribing an 
antibiotic for individual patients (correct drug based on the documented indication) and if 
the antibiotic was de-escalated appropriately (guideline-based, narrowest spectrum) when 
culture and susceptibility results were available.  The primary outcome of the study was 
the percentage of prescribers who adhered to the guideline-based pathways.  
Statistical Analysis:  
Continuous data was described using mean and standard deviation (SD) for variables 
considered to be normally distributed and median and interquartile range (IQR) for 
variables considered to be non-normally distributed.  Baseline demographics and clinical 
characteristics were compared between pre- and post-implementation period groups using 
independent samples t-tests, chi-squared analyses, and Mann-Whitney tests for non-
parametric data.  Chi-square analysis was used to compare the primary outcome and the 
appropriateness of antibiotic therapy in pre- and post-implementation periods.  P-values 
of less than 0.05 were considered statistically significant.  Statistical analyses were 
conducted using Statistical Package for Social Sciences version 23.0 (SPSS, Inc., 
Chicago).  
RESULTS 
A total of 381 patients were identified who met inclusion criteria with 121 and 260 
included in the pre- and post-ASP study groups, respectively.  Females comprised 64 
patients of the pre-ASP group (52.9%) and 138 patients of the post-ASP group (53.1%).  
The mean age of patients in the pre-ASP group was 60 years of age and 58 years of age 
in the post-ASP group.  The majority of patients in the cohort had no documented 
Bertram 11 
 
antibiotic allergies (n=288; 75.6%). Out of the 277 patients that had cultures obtained, 
217 were positive (78.3%).  Cultures were obtained for 108 patients (89.3%) in the pre-
ASP group with the majority (n=92; 85%) being urine cultures.  Ninety-two (85%) of all 
cultures obtained in the pre-ASP group were positive.  In the post-ASP group, cultures 
were obtained for 169 patients (65%) with the majority also being urine cultures (n=155; 
92%).  Positive cultures were documented in 125 patients (79%) of the post-ASP group.  
Appendix D lists the isolates found in each group.  The most prevalent isolates for both 
groups were Escherichia coli (23% of pre; 30% of post) and Klebsiella pneumoniae (16% 
of pre; 14% of post).  
Urinary tract infections were the most common infection for which antibiotics 
were prescribed (n=293; 76.9%).  Appendix E shows the prescribing rates for other 
included infections.  The three most common antibiotics prescribed were ciprofloxacin 
(n=101; 26.5%), sulfamethoxazole/trimethoprim (n=81; 21.3%), and nitrofurantoin 
(n=49; 12.9%).  First generation cephalosporins (n=31; 8.1%) and third generation 
cephalosporins (n=22; 5.8%) also had higher prescribing rates. A complete table of 
frequencies of antibiotic classes prescribed is shown in Appendix F.  
 Compliance to the guideline-based treatment pathways was found to be 81% in 
the pre-ASP group and 78.5% in the post-ASP group (p=0.571).  Appendix G shows 
compliance per quarter.  Overall compliance was found to be the highest (100% in both 
pre- and post-ASP groups) for osteomyelitis infections and CDI. Urinary tract infections 
had the next highest rate of compliance in both the pre- and post-ASP groups (86.5% and 
81.7% respectively).  Rates of compliance for pneumonia were 71.4% in the pre-ASP 
group and 72.7% in the post-ASP group.  Cellulitis infections had the lowest rates of 
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compliance with only 27.3% in the pre-ASP group and 52% in the post-ASP group.  
Compliance rates based on indication per quarter are displayed in Appendix H.   
 The three most common classes of antibiotics prescribed were fluoroquinolones, 
sulfonamides, and urinary agents (nitrofurantoin and fosfomycin).  In the pre-ASP group, 
prescribers utilized fluoroquinolones appropriately 95% of the time and 97.4% in the 
post-ASP group. Sulfonamides had a compliance rate of 88.5% in the pre-ASP group and 
85.5% in the post-ASP group.  Urinary agents had a higher rate of compliance with 95% 
in the pre-ASP group and 100% in the post-ASP group.  Appendix I displays compliance 
rates based on antibiotic class in both pre- and post-ASP groups.   
DISCUSSION 
In this cohort, we found no statistically significant difference in rates of prescriber 
compliance to guideline-based treatment pathways both before and after implementation 
of an antimicrobial stewardship program at RHI.  The 2016 Infectious Diseases Society 
of America/Society for Healthcare Epidemiology of America (IDSA/SHEA) guidelines 
“Implementing an Antibiotic Stewardship Program” recommend that ASPs develop 
facility-specific clinical practice guidelines and algorithms to standardize prescribing 
practices based on local epidemiology for common infectious diseases.11  Several studies 
have shown that the implementation of facility-specific guidelines has led to statistically 
significant increases in the likelihood of adequate initial therapy, use of narrower-
spectrum regimens, earlier switch from IV to oral therapy, and shorter duration of 
treatment without adversely affecting clinical outcomes.11  In this cohort, there was no 
difference in prescriber compliance to guideline-based treatment pathways both before 
and after implementation of an antimicrobial stewardship program at a rehabilitation 
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hospital.  While our study did not find a significant increase in appropriate antibiotic 
prescribing after facility-specific guideline-based treatment pathway implementation, it is 
reassuring that prescriber compliance remained consistent in all quarters except the first 
quarter following implementation.  
We hypothesized that a higher percentage of antimicrobial orders would be 
compliant with the guideline-based treatment pathways after implementation of an ASP 
in comparison with the period prior to ASP implementation.  There are several potential 
reasons as to why a significant increase in appropriate antibiotic prescribing was not 
found.  Although the official start of the ASP was documented as January 1, 2016, the 
program was not implemented all at once.  Accounting for the gradual implementation 
period where all the details were still being worked out may explain why compliance 
rates for Quarter 1 of 2016 were much lower than Quarters 2 and 3 of the post-
implementation group.  
 One of the largest factors contributing to the insignificant difference in rates of 
compliance to treatment guidelines may be a lack of formal prescriber education and/or 
lack of prescriber “buy-in” to the ASP and treatment pathways.  The ASP was presented 
to the Rehab Physicians Committee and the scope, objectives, measuring of utilization, 
guidelines were discussed and approved.  Since the program was approved and supported 
by leadership present in the committee, all physicians are expected to comply with the 
program.  However, there were never any formal educational sessions held with 
physicians and medical residents at RHI to introduce them to the program, educate them 
on how to utilize the treatment pathways, or explain the process for ordering restricted 
antimicrobials.  Because of this lack of formally delivered information, physicians may 
Bertram 14 
 
not understand the benefit and importance of the ASP and may be hesitant to change their 
prescribing habits.  Education is an essential element of an ASP to influence prescribing 
behavior and increase the acceptance of stewardship strategies.15   Regularly scheduled 
education sessions would likely aid prescribers in understanding how to utilize the 
outlined treatment pathways, the benefits of the ASP, and which areas to focus on for 
improvement in compliance (i.e. specific infection, antibiotic class, etc.).  
The IDSA/SHEA guidelines for developing an institutional program to enhance 
antimicrobial stewardship outline core strategies which should be incorporated into all 
stewardship programs.  The core strategies include two methods to impact antimicrobial 
use in hospitals: preauthorization and prospective audit and feedback.14  ASPs should 
decide whether to include one strategy or a combination of both based on availability of 
facility-specific resources.11  Preauthorization, or formulary restriction, is a strategy in 
which the ASP creates a formulary and decides which antimicrobials will require 
authorization before they can be prescribed.11 Although RHI has developed a list of 
restricted antimicrobial agents (Appendix A) and antimicrobials which require an internal 
medicine or infectious disease consult (Appendix B), there is currently no formal system 
in place to stop prescribers from ordering an antimicrobial on one of those lists.  It is the 
sole responsibility of the clinical pharmacist to recognize the antimicrobial as restricted 
and initiate contact with the prescriber to verify proper indication.  According to the 
updated 2016 IDSA/SHEA guidelines, outcome studies from preauthorization have 
shown decreased antibiotic use and resistance, particularly among gram-negative 
pathogens, while not displaying any adverse effects for patients.11  In one study, the 
initiation of preauthorization in a county teaching hospital was associated with a 32% 
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decrease in total parenteral antibiotic expenditures and increased susceptibility of gram-
negative isolates.11  If RHI could incorporate a hard or soft stop into their electronic 
antibiotic order set when prescribers attempt to order a restricted antimicrobial, it would 
likely minimize the incidence that these agents are used inappropriately, and may 
increase compliance to the treatment pathways.  
The second approach, or prospective audit with intervention and feedback (PAF), 
requires ASP clinical pharmacists or infectious disease physicians to review antimicrobial 
appropriateness after they are prescribed and provide feedback to the prescriber.11  Unlike 
preauthorization alone, this approach does impact resistance to a greater degree due to its 
usefulness in antimicrobial de-escalation and appropriate duration of therapy.15  
However, PAF is more time and resource-intensive, especially in the setting of a larger 
hospital.14  The IDSA/SHEA guidelines report that PAF interventions have also been 
shown to improve antibiotic use, reduce resistance, and reduce CDI rates without 
negatively impacting patient outcomes.11  RHI would eventually like to implement a 48-
hour stop for antimicrobial review in which a clinician evaluates if the antimicrobial is 
still necessary, is de-escalated appropriately based on culture data, and has a stop date 
entered.  This is currently being piloted at two other facilities within the hospital network 
and would likely decrease the incidence of inappropriate duration and utilization of 
empiric antimicrobial therapy.  
There are limitations to this study including its retrospective design and relatively 
small sample size.  Our study likely lacked necessary power.  The inherent limitations of 
chart documentation and the variable availability of certain information could have 
affected our results.  In many instances, it was difficult to find a clearly documented 
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indication for antimicrobial therapy.  If an indication was listed, it was rare for 
prescribers to document the type/severity of the infection, making it challenging to assess 
the appropriateness of the prescriber’s choice in antimicrobial agent.  The retrospective 
nature of our study made it difficult to understand all prescriber considerations at the time 
of antibiotic regimen formulation.  The prescriber may have known more about a specific 
patient than what was documented in the electronic medical record, warranting them to 
choose one antibiotic over another recommended in the guideline-based pathway.  
At the start of the study, compliance was originally defined as both correct drug 
and correct duration based on indication since appropriate antibiotic duration guidelines 
are also included on the treatment pathways for each infection.  However, throughout the 
data collection process, it became difficult to track days of antibiotic therapy for patients 
at RHI due to the nature of the institution.  In the rehabilitation hospital setting, patients 
could be admitted on antibiotics, be admitted to an acute hospital during their course of 
antimicrobial therapy and then readmitted to RHI, or be discharged on antimicrobial 
therapy, making total days of therapy difficult to determine.  It is important to consider 
that many factors contribute to appropriate antimicrobial usage besides appropriate drug 
choice, including appropriate dose, duration, de-escalation, and administration.  This 
warrants a need for future studies to evaluate all of these components.  
CONCLUSIONS 
In this retrospective cohort study, no significant difference in rates of prescriber 
compliance to guideline-based treatment pathways was found after the implementation of 
an ASP.  Urinary tract infections were found to be the most common indication requiring 
antimicrobial usage at RHI and had the third highest rate of compliance out of the 
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infections included in this study.  Fluoroquinolones, sulfonamides, and urinary agents 
were the most prescribed antibiotic classes and were utilized appropriately 85-100% of 
the time in both the pre- and post-ASP groups.  
 Our study highlights a need for further investigation regarding the impact of the 
ASP on appropriate antimicrobial dose, duration of therapy, administration, and de-
escalation based on culture data.  Additionally, our study identified a need for formal 
prescriber education focusing on how to utilize the treatment pathways, especially for 
those infections with the lowest compliance rates.  The rates of antimicrobial resistance, 
adverse events, and cost savings at RHI pre- and post-ASP implementation are areas of 
future study.  
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Appendix A 
Restricted Antimicrobials 
Amphotericin B lipid complex 
Serum creatinine >2 or 50% decrease in 
baseline renal function 
 
Amphotericin B failure 
 
ID consult 
Cefepime 
Penicillin-allergic patients 
 
Organisms resistant to 
piperacillin/tazobactam 
 
CNS infections 
Linezolid VRE and all alternatives resistant 
Posaconazole Transplant patients 
Voriconazole Transplant patients 
 
Appendix B 
Antimicrobials that require an Internal Medicine or Infectious Disease Consult   
Ertapenem Moxifloxacin Daptomycin 
Carbapenem Tigecycline Micafungin 
 
Appendix C 
Appropriate Antibiotics by Indication per Guideline-Based Treatment Pathways  
Indication Empiric Therapy Directed Therapy 
Pneumonia 
Cefepime or Ceftazidime or 
Meropenem or 
Piperacillin/tazobactam 
PLUS 
Levofloxacin or Gentamicin 
PLUS 
Vancomycin 
Piperacillin/tazobactam 
Piperacillin/tazobactam 
PLUS gentamicin 
Meropenem 
Vancomycin or linezolid 
Osteomyelitis 
Vancomycin 
Vancomycin PLUS 
piperacillin/tazobactam 
Ampicillin/sulbactam 
Cefazolin 
Ceftriaxone 
Piperacillin/tazobactam 
Ampicillin/sulbactam 
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UTI 
Nitrofurantoin 
SMX/TMP 
Fosfomycin 
Ciprofloxacin 
Ceftriaxone 
Levofloxacin 
Gentamicin 
Ciprofloxacin 
Levofloxacin 
Amoxicillin/clavulanate 
Cefdinir 
SMX/TMP 
 
Febrile Neutropenia 
Ciprofloxacin PLUS 
amoxicillin/clavulanate 
Piperacillin/tazobactam  
 Meropenem  
 Ceftazidime 
 Cefepime 
Meropenem 
Vancomycin 
Daptomycin 
Linezolid 
Gentamicin 
Tigecycline 
CDI 
Metronidazole +/- 
Vancomycin 
Metronidazole and/or 
Vancomycin 
Cellulitis 
Penicillin VK 
Ceftriaxone 
Cefazolin/cephalexin 
Clindamycin 
Vancomycin PLUS 
piperacillin/tazobactam 
Penicillin VK 
Ceftriaxone 
Cefazolin/cephalexin 
Clindamycin 
Vancomycin PLUS 
piperacillin/tazobactam 
Catheter-Related 
Bloodstream Infection 
Vancomycin +/- 
Piperacillin/tazobactam +/- 
Micafungin 
Nafcillin 
Vancomycin 
Ampicillin 
Ceftriaxone 
Meropenem 
Ampicillin/sulbactam 
Piperacillin/tazobactam 
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Appendix D 
Isolates from Positive Cultures  
Pre-ASP (N=91) Post-ASP (N=125) 
Isolate Frequency Percent Isolate Frequency Percent 
E.coli 21 23.1% E.coli 38 30.4% 
Klebsiella 
pneumoniae 
15 16.4% 
Klebsiella 
pneumoniae 
17 13.6% 
Coag-negative 
staphylococcus 
3 3.3% 
Coag-negative 
staphylococcus 
5 4% 
E. coli ESBL 5 5.5% E. coli ESBL 4 3.2% 
Pseudomonas 9 9.9% Pseudomonas 10 8% 
Enterococcus 4 4.4% Enterococcus 6 4.8% 
Enterobacter 
aerogenes 
2 2.2% 
Enterobacter 
aerogenes 
2 1.6% 
Citrobacter  3 3.3% Citrobacter  2 1.6% 
Enterobacter 
cloacae 
4 4.4% 
Enterobacter 
cloacae 
6 4.8% 
C. difficile 3 3.3% C. difficile 4 3.2% 
Enterococcus 
faecium VRE 
1 1.1% 
Enterococcus 
faecium VRE 
2 1.6% 
Streptococcus 1 1.1% Streptococcus 2 1.6% 
Klebsiella oxytoca 1 1.1% 
Klebsiella 
oxytoca 
2 1.6% 
Serratia 2 2.2% 
Proteus 
mirabilis 
8 6.4% 
Stenotrophomonas 1 1.1% Lactobacillus 1 0.8% 
Multiple  16 17.6% Multiple 15 12% 
   
Providencia 
stuartii 
1 0.8% 
 
Appendix E 
Antibiotics Prescribed Based on Indication 
Indication Frequency (N=381) Percent 
UTI 293 76.9% 
Cellulitis 36 9.4% 
Pneumonia 29 7.6% 
CDI 17 4.5% 
Osteomyelitis 4 1% 
Febrile Neutropenia 1 0.3% 
UTI and cellulitis 1 0.3% 
Catheter-related 
Bloodstream Infection 
0 0% 
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Appendix F 
Antibiotics Prescribed Based on Class 
Antibiotic Class Frequency (N=381) Percent 
Fluoroquinolone 118 31% 
Sulfonamide 81 21.3% 
Urinary  55 14.4% 
1st generation cephalosporin 31 8.1% 
3rd generation 
cephalosporin 
22 5.8% 
Glycopeptide 16 4.2% 
Anaerobic  12 3.1% 
Beta-lactamase inhibitor 12 3.1% 
4th generation 
cephalosporin 
10 2.6% 
Penicillin 8 2.1% 
Lincosamide 5 1.3% 
Tetracycline 4 1% 
2nd generation 
cephalosporin 
3 0.8% 
Macrolide 2 0.5% 
Aminoglycoside 1 0.3% 
Miscellaneous 1 0.3% 
 
Appendix G 
Compliance per Quarter 
Group Quarter Frequency Percent 
Cumulative 
Percent 
Pre-ASP 
(N=121) 
Quarter 4 2015 
(N=121) 
98 81% 81% 
Post-ASP 
(N=260) 
Quarter 1 2016 
(N=121) 
90 74.4% 
78.5% 
Quarter 2 2016 
(N=83) 
68 81.9% 
Quarter 3 2016 
(N=56) 
46 82.1% 
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Appendix H 
Compliance based on Indication per Quarter 
Indication Group Quarter 
Compliant (N 
(%)) 
Cumulative 
Percent 
UTI 
(N=293) 
Pre-ASP 
(N=96) 
Quarter 4 2015 
(N=96) 
83 (86.5%) 86.5% 
Post-ASP 
(N=197) 
Quarter 1 2016 
(N=99) 
76 (76.8%) 
83.4% 
Quarter 2 2016 
(N=55) 
48 (87.3%) 
Quarter 3 2016 
(N=43) 
37 (86%) 
Pneumonia 
(N=29) 
Pre-ASP 
(N=7) 
Quarter 4 2015 
(N=7) 
5 (71.4%) 71.4% 
Post-ASP 
(N=22) 
Quarter 1 2016 
(N=9) 
5 (55.6%) 
73.2% 
Quarter 2 2016 
(N=9) 
8 (88.9%) 
Quarter 3 2016 
(N=4) 
3 (75%) 
Cellulitis 
(N=36) 
Pre-ASP 
(N=11) 
Quarter 4 2015 
(N=11) 
3 (27.3%) 27.3% 
Post-ASP 
(N=25) 
Quarter 1 2016 
(N=7) 
4 (57.1%) 
53.2% 
Quarter 2 2016 
(N=10) 
4 (40%) 
Quarter 3 2016 
(N=8) 
5 (62.5%) 
CDI 
 (N=17) 
Pre-ASP 
(N=6) 
Quarter 4 2015 
(N=6) 
6 (100%) 100% 
Post-ASP 
(N=11) 
Quarter 1 2016 
(N=5) 
5 (100%) 
100% 
Quarter 2 2016 
(N=5) 
5 (100%) 
Quarter 3 2016 
(N=1) 
1 (100%) 
Osteomyelitis 
(N=4) 
Pre-ASP 
(N=1) 
Quarter 4 2015 
(N=1) 
1 (100%) 100% 
Post-ASP 
(N=3) 
Quarter 2 2016 
(N=3) 
3 (100%) 100% 
Neutropenia 
(N=1) 
Post-ASP 
(N=1) 
Quarter 1 2016 
(N=1) 
0 (0%) 0% 
UTI and 
cellulitis 
(N=1) 
Post-ASP 
(N=1) 
Quarter 2 2016 
(N=1) 
0 (0%) 0% 
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Appendix I  
Compliance based on Antibiotic Class per Group  
Antibiotic Class Group 
 
Compliant (N (%)) 
 
Fluoroquinolone (N=118) 
Pre-ASP (N=40) 38 (95%) 
Post-ASP (N=78) 76 (97.4%) 
Sulfonamide (N=81) 
Pre-ASP (N=26) 23 (88.5%) 
Post-ASP (N=55) 47 (85.5%) 
Urinary (N=55) 
Pre-ASP (N=20) 19 (95%) 
Post-ASP (N=35) 35 (100%) 
1st generation cephalosporin 
(N=31) 
Pre-ASP (N=4) 2 (50%) 
Post-ASP (N=27) 12 (44.4%) 
3rd generation cephalosporin 
(N=22) 
Pre-ASP (N=8) 6 (75%) 
Post-ASP (N=14) 7 (50%) 
Glycopeptide (N=16) 
Pre-ASP (N=3) 2 (66.7%) 
Post-ASP (N=13) 11 (84.6%) 
Anaerobic (N=12) 
Pre-ASP (N=5) 5 (100%) 
Post-ASP (N=7) 7 (100%) 
Beta-lactamase inhibitor (N=12) 
Pre-ASP (N=4) 0 (0%) 
Post-ASP (N=8) 4 (50%) 
Penicillin (N=8) 
Pre-ASP (N=2) 0 (0%) 
Post-ASP (N=6) 0 (0%) 
Macrolide (N=2) 
Pre-ASP (N=0) n/a 
Post-ASP (N=2) 2 (100%) 
Tetracycline (N=4) Pre-ASP (N=0) n/a 
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Post-ASP (N=4) 0 (0%) 
2nd generation cephalosporin 
(N=3) 
Pre-ASP (N=2) 2 (100%) 
Post-ASP (N=1) 0 (0%) 
4th generation cephalosporin 
(N=10) 
Pre-ASP (N=5) 0 (0%) 
Post-ASP (N=5) 1 (20%) 
Lincosamide (N=5) 
Pre-ASP (N=2) 1 (50%) 
Post-ASP (N=3) 1 (33.3%) 
Aminoglycoside (N=1) 
Pre-ASP (N=0) n/a 
Post-ASP (N=1) 1 (100%) 
Miscellaneous (N=1) 
Pre-ASP (N=0) n/a 
Post-ASP (N=1) 0 (0%) 
 
